Document:

Exhibit 10.2

 

EXCHANGE AGREEMENT

 

EXCHANGE AGREEMENT (this
"Agreement"), dated as of November 15th, 2015, by and between Apptigo International, Inc. a Nevada corporation,
with offices located at 1801 SW 3rd Avenue, Suite 402, Miami, Florida 33129 (the "Company"), and Anthony Ivankovich
having an address at _____________________________________(the "Holder").

 

WHEREAS:

 

A. The Holder is the owner
of a convertible note in the aggregate principal amount of $350,000, dated __________, 2014 (the "Convertible Note").

 

B. The Company and the
Holder desire to enter into this Agreement, pursuant to which, among other things, the Holder shall exchange the Convertible Note
for a 10% Convertible Debenture in the original principal amount of $350,000 in the form of Exhibit "A" attached
hereto (the "Exchange Note") in reliance upon the exemption from registration provided by Section 3(a) (9) of the Securities
Act, as amended (the "Securities Act"); and

 

C. In addition to the terms
defined elsewhere in this Agreement, the following terms have the meanings set forth below:

 

"Affiliate"
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

"Board of Directors"
means the board of directors of the Company.

 

"Business Day"
means any day except Saturday, Sunday, any day which is a federal legal holiday in the United States or any day on which banking
institutions in the State of Florida are authorized or required by law or other governmental action to close.

 

"Liens"
means a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

   

"Trading Market"
means the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the
OTCQX or the OTCQB.

 

"Transfer Agent"
means Interwest Transfer Co., Inc. having an address of 1981 Murray Holladay Road, Suite 100, Salt Lake City, UT 84117.

 

 

 

    	1

     

    

 

NOW, THEREFORE,
in consideration of the foregoing recitals and the mutual promises hereinafter set forth, the Company and the Holder hereby agree
as follows:

 

1.        Exchange of Convertible
Note      On the date hereof, the Holder shall, and the Company shall, pursuant to Section 3(a)(9) of the Securities Act,
exchange the Convertible Note for the Exchange Note, without the payment of any additional consideration (the "Exchange"),
as follows:

 

(a) Delivery.
In exchange for the Convertible Note, on the date hereof the Company shall issue to the Holder the Exchange Note. The Holder shall
deliver or cause to be delivered to the Company the Convertible Note on the date hereof. Promptly following the issuance of the
Exchange Note to the Holder, the Convertible Note shall be cancelled.

 

(b) Other Documents.
The Company and the Holder shall execute and/or deliver such other documents and agreements as are customary and reasonably necessary
to effectuate the Exchange.

 

2.       Representations
and Warranties

 

Holder Representations
and Warranties. The Holder hereby represents and warrants to the Company that, as of the date hereof, the Holder is the sole
owner of the Convertible Note and will transfer and deliver to the Company at the Closing the Convertible Note, free from any liens,
charges and other encumbrances.

 

3.        Miscellaneous

 

(a) Waivers.
The waiver of a breach of this Agreement or the failure of any party hereto to exercise any right under this Agreement shall in
no way constitute waiver as to future breach whether similar or dissimilar in nature or as to the exercise of any further right
under this Agreement.

  

(b) Amendment.
This Agreement may be amended or modified only by an instrument of equal formality signed by the Parties or the duly authorized
representatives of the respective Parties.

 

(c) Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Florida, without giving
effect to conflict of laws. Any action, suit, or proceeding arising out of, based on, or in connection with this Agreement, any
document relating hereto or delivered in connection with the transactions contemplated hereby, any statement, certificate, or other
instrument delivered by or on behalf of, or delivered to, any party hereto or thereto in connection with the transactions contemplated
hereby or thereby, any breach of this Agreement or such other document, or the other transactions contemplated hereby or thereby
may be brought only in the state courts of the State of Florida located in Miami Dade County, or in the United States District
Court for the Southern District of Florida and each party covenants and agrees not to assert, by way of motion, as a defense, or
otherwise, in any such action, suit, or proceeding, any claim that it is not subject personally to the jurisdiction of such court
if it has been duly served with process, that its property is exempt or immune from attachment or execution, that the action, suit,
or proceeding is brought in an inconvenient forum, that the venue of the action, suit, or proceeding is improper, or that this
Agreement or the subject matter hereof may not be enforced in or by such court. Each party hereby irrevocably waives personal service
of process and consents to process being served in any suit, action or proceeding in connection with this Agreement by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
sin effect for notice under this Agreement and agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner
permitted by law. The Company and the Holder waive trial by Jury. The prevailing party shall be entitled to recover from the other
party its reasonable attorney's fees and costs.

 

    	2

     

    

 

(d) Assignment.
This Agreement is not assignable except by operation of law.

 

(e) Entire Agreement.
This Agreement and the Exchange Note and the documents issued in connection with these documents contains the entire agreement
among the Parties with respect to the transactions contemplated hereby, and supersedes all prior agreements, written or oral, with
respect hereof.

 

(f) Counterparts.
This Agreement may be executed in any number of counterparts, each of which when so executed, shall constitute an original copy
hereof, but all of which together shall consider but one and the same document.

 

IN WITNESS WHEREOF, the
Holder and the Company have duly executed this Agreement as of the date first written above.

 

 

COMPANY

 

APPTIGO INTERNATIONAL, INC.

 

 

By: /s/ David Steinberg

Name: David Steinberg

Title: President

 

 

HOLDER

 

 

/s/ Anthony Ivankovich

Anthony Ivankovich 

 

 

 

    	3

    

 

 

 

Exhibit A

 

Convertible DebentureExhibit 4.12

 

FIRST AMENDMENT TO THE

CANCER PREVENTION PHARMACEUTICALS, INC.

2010 EQUITY INCENTIVE PLAN

 

 

This First Amendment to the Cancer Prevention
Pharmaceuticals, Inc. 2010 Equity Incentive Plan (the “Plan”) is effective March 29, 2012.

 

WHEREAS, the Board of Directors of Cancer
Prevention Pharmaceuticals, Inc., a Delaware corporation (the “Company”) has adopted and the stockholders of
the Company have approved the Plan, as amended; and

 

WHEREAS, the Board of Directors deems it
to be in the best interest of the Corporation to amend the Plan in order to increase the maximum number of shares of common stock
that may be subject to Awards and sold under the Plan from 200,000 shares to 265,000.

 

NOW, THEREFORE, the Plan shall be amended
as follows:

 

		1.	Section 3(a) shall be deleted in its entirety and the following substituted in lieu thereof:

 

“3(a) Stock Subject to the Plan.
Subject to the provisions of Section 11 of the Plan, the maximum aggregate number of Shares that may be subject to Awards and sold
under the Plan is 265,000 Shares. The Shares may be authorized but unissued, or reacquired Common Stock.”

 

		2.	Except as amended herein, the terms and provision of the Plan shall remain unchanged and in full force and effect.

 

IN WITNESS WHEREOF, the undersigned Chairman
and Chief Executive Officer of the Company certifies that the foregoing First Amendment of the Cancer Prevention Pharmaceuticals,
Inc. 2010 Equity Incentive Plan was duly adopted by the Board of Directors of the Company.

 

 

	 	 	 	 
	 	CANCER PREVENTION PHARMACEUTICALS, INC.	 
	 	 	 	 
	 	By:	/s/ Jeffrey Jacob	 
	 	 	
        Jeffrey Jacob, Chairman and

        Chief Executive OfficerExhibit 4.13

 

SECOND AMENDMENT TO THE

CANCER PREVENTION PHARMACEUTICALS, INC.

2010 EQUITY INCENTIVE PLAN

 

 

This Second Amendment to the Cancer Prevention
Pharmaceuticals, Inc. 2010 Equity Incentive Plan (the “Plan”) is effective September 27, 2012.

 

WHEREAS, the Board of Directors of Cancer
Prevention Pharmaceuticals, Inc., a Delaware corporation (the “Company”) has adopted and the stockholders of
the Company have approved the Plan, as amended; and

 

WHEREAS, the Board of Directors deems it
to be in the best interest of the Corporation to amend the Plan in order to increase the maximum number of shares of common stock
that may be subject to Awards and sold under the Plan from 265,000 shares to 300,000.

 

NOW, THEREFORE, the Plan shall be amended
as follows:

 

		1.	Section 3(a) shall be deleted in its entirety and the following substituted in lieu thereof:

 

“3(a) Stock Subject to the Plan.
Subject to the provisions of Section 11 of the Plan, the maximum aggregate number of Shares that may be subject to Awards and sold
under the Plan is 300,000 Shares. The Shares may be authorized but unissued, or reacquired Common Stock.”

 

		2.	Except as amended herein, the terms and provision of the Plan shall remain unchanged and in full force and effect.

 

IN WITNESS WHEREOF, the undersigned Chairman
and Chief Executive Officer of the Company certifies that the foregoing Second Amendment of the Cancer Prevention Pharmaceuticals,
Inc. 2010 Equity Incentive Plan was duly adopted by the Board of Directors of the Company.

 

 

	 	 	 	 
	 	CANCER PREVENTION PHARMACEUTICALS, INC.	 
	 	 	 	 
	 	By:	/s/ Jeffrey Jacob	 
	 	 	
        Jeffrey Jacob, Chairman and

        Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]